|
Gene: FAM65B |
Gene summary for FAM65B |
Gene summary. |
Gene information | Species | Human | Gene symbol | FAM65B | Gene ID | 9750 |
Gene name | RHO family interacting cell polarization regulator 2 | |
Gene Alias | C6orf32 | |
Cytomap | 6p22.3 | |
Gene Type | protein-coding | GO ID | GO:0000768 | UniProtAcc | B7Z5J9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9750 | FAM65B | HCC1 | Human | Liver | HCC | 2.38e-20 | 1.98e+00 | 0.5336 |
9750 | FAM65B | HCC2 | Human | Liver | HCC | 1.13e-38 | 3.10e+00 | 0.5341 |
9750 | FAM65B | HCC5 | Human | Liver | HCC | 1.76e-71 | 3.43e+00 | 0.4932 |
9750 | FAM65B | Dong_P1 | Human | Prostate | Tumor | 4.27e-02 | 5.06e-02 | 0.035 |
9750 | FAM65B | Dong_P3 | Human | Prostate | Tumor | 2.85e-07 | 1.28e-01 | 0.0278 |
9750 | FAM65B | P7 | Human | Prostate | Tumor | 1.67e-02 | 2.54e-01 | -0.1025 |
9750 | FAM65B | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 3.71e-02 | 5.52e-01 | 0.159 |
9750 | FAM65B | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 2.78e-04 | 2.86e-01 | 0.1633 |
9750 | FAM65B | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 4.96e-07 | 3.36e-01 | 0.1621 |
9750 | FAM65B | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.41e-03 | 4.31e-01 | 0.1619 |
9750 | FAM65B | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 5.40e-10 | 5.31e-01 | 0.1602 |
9750 | FAM65B | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 5.78e-05 | 4.28e-01 | 0.1608 |
9750 | FAM65B | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 3.09e-16 | 5.97e-01 | 0.1575 |
9750 | FAM65B | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 4.84e-16 | 6.19e-01 | 0.1545 |
9750 | FAM65B | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 1.16e-18 | 7.45e-01 | 0.1569 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease | ||
Prostate | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM65B | SNV | Missense_Mutation | novel | c.577N>T | p.Ile193Phe | p.I193F | Q9Y4F9 | protein_coding | tolerated(0.24) | possibly_damaging(0.888) | TCGA-37-A5EN-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
FAM65B | SNV | Missense_Mutation | c.1199C>G | p.Pro400Arg | p.P400R | Q9Y4F9 | protein_coding | tolerated(0.22) | benign(0.371) | TCGA-66-2754-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
FAM65B | SNV | Missense_Mutation | novel | c.1456N>C | p.Ser486Pro | p.S486P | Q9Y4F9 | protein_coding | tolerated(0.16) | benign(0.354) | TCGA-66-2769-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
FAM65B | SNV | Missense_Mutation | novel | c.1421N>T | p.Gln474Leu | p.Q474L | Q9Y4F9 | protein_coding | tolerated(0.29) | benign(0.075) | TCGA-77-7141-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FAM65B | SNV | Missense_Mutation | novel | c.167N>G | p.His56Arg | p.H56R | Q9Y4F9 | protein_coding | deleterious(0.01) | benign(0.137) | TCGA-77-7465-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FAM65B | SNV | Missense_Mutation | novel | c.360N>C | p.Lys120Asn | p.K120N | Q9Y4F9 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-NC-A5HD-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FAM65B | deletion | Frame_Shift_Del | c.198delN | p.Glu68SerfsTer14 | p.E68Sfs*14 | Q9Y4F9 | protein_coding | TCGA-NC-A5HP-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | PD | |||
FAM65B | SNV | Missense_Mutation | novel | c.175G>T | p.Gly59Cys | p.G59C | Q9Y4F9 | protein_coding | deleterious(0.01) | probably_damaging(0.982) | TCGA-CN-5360-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD |
FAM65B | SNV | Missense_Mutation | rs202204524 | c.1723G>C | p.Glu575Gln | p.E575Q | Q9Y4F9 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-CR-7388-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
FAM65B | SNV | Missense_Mutation | novel | c.223G>C | p.Glu75Gln | p.E75Q | Q9Y4F9 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-CR-7388-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |